Hasil Pencarian  ::  Simpan CSV :: Kembali

"STEMI adalah IMA dengan risiko mortalitas tinggi. Risiko dikurangi dengan revaskularisasi berupa IKPP Gangguan kardiovaskular dikaitkan dengan penurunan konsentrasi vitamin D. Penurunan bisa disebabkan SNP gen CYP27B1 yang mengkode enzim 1α hidroksilase dan belum ada penelitian yang menghubungkan konsentrasi vitamin D pada pasien STEMI yang menjalani IKPP. Hasil IKPP berupa area sumbatan dan kemampuan darah mengalir ke pembuluh darah koroner, dikenal dengan TIMI grade 0-3. Penelitian bertujuan untuk menganalisis hubungan konsentrasi kalsidiol dan gen CYP27B1 (-rs10877012) perubahan G ke T pada pasien STEMI yang menjalani IKPP dengan aliran TIMI akhir. Seratus subjek STEMI dan kontrol diambil 3 mL darah. Plasmanya diukur konsentrasi kalsidiol dengan teknik ELISA. PBMC dianalisis gen CYP27B1 (- rs10877012) dengan qRT PCR teknik Taqman Probe. Data dianalisis statistik kemaknaan 0,05. Konsentrasi kalsidiol median kasus 35,94 ng/ml dan kontrol 20,89 ng/ml berbeda bermakna (p=0,0001). Variasi gen CYP27B1 pada kedua kelompok berbeda bermakna (p=0,0001), dengan polimorfisme TT kasus 28% dan kontrol 19%. Hubungan konsentrasi kalsidiol dengan polimorfisme gen CYP27B1 berbeda bermakna (p=0,0001), tidak terdapat hubungan konsentrasi kalsidiol dengan aliran TIMI dan polimorfisme gen CYP27B1 dengan p=0,232. Konsentrasi kalsidiol tinggi pada kasus dimungkinkan sebagai respon tubuh terhadap inflamasi yang mengalami serangan jantung. Polimorfisme TT kasus 28% tidak memiliki hubungan terhadap patofisiologi aliran TIMI akhir.

---

STEMI is an AMI with a high risk of mortality. The risk is reduced by revascularization called by IKPP Cardiovascular disorders are associated with decreased vitamin D concentrations. The decrease could be due to the SNP gene CYP27B1 which encodes the enzyme 1α hydroxylase and no studies have linked vitamin D concentrations in STEMI patients undergoing IKPP. IKPP results in the form of block area and the ability of blood to flow to the coronary blood vessels, known as TIMI grade 0-3. The aim of this study was to analyze the relationship between calcidiol concentrations and the CYP27B1 gene (-rs10877012) G to T changes in STEMI undergoing IKPP with TIMI flow. One hundred STEMI and control subjects collected 3 mL of blood. Plasma concentration of calcidiol was measured using the ELISA technique. PBMCs were analyzed CYP27B1 gene (- rs10877012) by taqman probe qRT PCR. Data were analyzed by statistical significance of 0.05. Median calcidiol concentration of 35.94 ng / ml cases and 20.89 ng / ml controls was significantly different (p = 0.0001). CYP27B1 gene variation in the two groups was significantly different (p = 0.0001), with TT polymorphism of 28% and 19% of controls. The correlation between calcidiol concentration and CYP27B1 gene polymorphism was significantly different (p = 0.0001), there was no correlation between calcidiol concentration and TIMI flow and CYP27B1 gene polymorphism with p = 0.232. The high calcidiol concentration in this case may be the body's response to inflammation following a heart attack. The TT polymorphism of 28% cases had no relationship to the pathophysiology of late TIMI flow."

"Polimorfisme CYP2C19 menurunkan metabolisme klopidogrel dan telah diketahui meningkatkan mortalitas serta kejadian kardiovaskular mayor. VerifyNow P2Y12 merupakan salah satu pemeriksaan yang secara spesifik menggambarkan fungsi platelet terhadap agen penghambat P2Y12 yang dikonsumsi. Hubungan antara polimorfisme CYP2C19 dengan TIMI flow pada populasi Asia, khususnya Indonesia, belum pernah dilakukan.Penelitian ini bertujuan untuk mengetahui hubungan antara polimorfisme CYP2C19 terhadap fungsi penghambatan platelet dan TIMI flow, serta hubungan antara fungsi penghambatan platelet dan TIMI flow.Dilakukan pemeriksaan polimorfisme CYP2C19 dengan menggunakan metode Taqman dan pemeriksaan fungsi penghambatan platelet yang diukur dengan VerifyNow P2Y12 pada 90 pasien IMA-EST yang menjalani IKPP yang memenuhi kriteria penelitian.Dari 90 subyek penelitian, studi polimorfisme genetik mengungkapkan 23,3% pasien dengan alel * 2, 11,2% dari * 3 alel pembawa, dan 1,1% membawa kedua alel. 24,4% pasien tergolong non-responder terhadap klopidogrel. Secara keseluruhan tidak terdapat hubungan secara langsung antara polimorfisme CYP2C19 dengan TIMI flow 3, namun terdapat hubungan antara polimorfisme CYP2C19 dengan penurunan fungsi penghambatan platelet (OR 4.7, p = 0.030). Indeks reaktivitas platelet >208 PRU meningkatkan risiko TIMI flow < 3 (OR 3.3, p= 0.046).Tidak terdapat hubungan secara langsung antara polimorfisme CYP2C19 dengan TIMI flow, namun pasien dengan polimorfisme CYP2C19*2 dan/atau *3 memiliki risiko untuk mengalami penurunan penghambatan fungsi platelet. Pasien yang tergolong non-responder terhadap klopidogrel ini juga berisiko untuk mendapatkan reperfusi miokard yang suboptimal.

---

CYP2C19 polymorphism plays an important role in clopidogrel metabolism. The genetic factor is VerifyNow P2Y12 is an examination that specifically describes platelet function against P2Y12 inhibitors. It is unknown whether platelet reactivity measured by P2Y12 reaction unit (PRU) is affected by CYP2C19 polymorphism or predictive of TIMI flow in Asian populations, particularly in Indonesia. We sought to define whether polymorphisms on CYP2C19 genes and platelet reactivity may affect the myocardial perfusion.

STEMI patients who underwent primary PCI and has received 600 mg loading dose of clopidogrel were recruited for the study. We measured platelet reactivity by VerifyNow P2Y12, high platelet reactivity was defined as > 208 PRU. Genetic polymorphisms analysis to assess the presence of CYP2C19*2 and *3 alleles on each patient were performed by Taqman method.

There were 90 patients recruited for study. Genetic polymorphisms studies revealed 23.3% of patients with *2 allele, 11.2% of *3 allele carriers, and 1.1% carried both allele. 23.4% of patients were clopidogrel non-responders. Overall, there was no correlation between CYP2C19 polymorphism and TIMI flow < 3, but there was a relationship between CYP2C19 polymorphism and decreased function of platelet inhibition (OR 4.7, p = 0.030). Platelet reactivity index > 208 increased the risk of suboptimal reperfusion (OR 3.3, p = 0.046).

There is no direct relationship between CYP2C19 polymorphism and TIMI flow, but patients with CYP2C19*2 and/or CYP2C19*3 had increased risk of being clopidogrel non responders. After adjusted to confounding factors, VerifyNow > 208 PRU is associated with suboptimal myocardial reperfusion."

"ABSTRAKGen CYP2C8 mempunyai beberapa alel mutan yang menyandi enzim CYP2C8 dengan kapasitas metabolisme yang rendah. Enzim CYP2C8 berperanan penting dalam metabolisme antimalaria amodiakuin menjadi metabolit aktifnya desetilamodiakuin sehingga mutasi pada gen CYP2C8 diduga berpotensi menyebabkan kegagalan terapi maupun kejadian efek samping agranulositosis yang dipicu oleh metabolit nonenzimatiknya amodiakuinkuinonimin.Penelitian observasional ini bertujuan untuk mengetahui frekuensi distribusi alel mutan gen CYP2C8 yaitu CYP2C8*2, CYP2C8*3, dan CYP2C8*4 pada salah satu kelompok etnik yang tinggal di daerah endemik malaria, yaitu suku Nias. Analisis PCR-RFLP untuk identifikasi alel gen CYP2C8 yang dilakukan pada 214 sampel berupa tetes darah di kertas saring (dot blot) dan subjek suku Nias memperlihatkan bahwa semua sampel membawa alel normal (wild type). Dengan tidak ditemukannya alel mutan gen CYP2C8 pada suku Nias, kita dapat berharap bahwa kemungkinan kegagalan terapi amodiakuin dan efek samping obat akibat metabolit nonenzimatiknya pada suku Nias tidak berkaitan dengan polimorfisme gen CYP2C8.

---

ABSTRACTThe CYP2C8 gene has been documented to have several alleles encoding enzyme with low metabolic capacity. Since CYP2C8 plays a major role in metabolizing antimalarial drug amodiaquine to its active metabolite desethylamodiaquine, it is assumed that mutation in CYP2C8 gene may potentially lead to treatment failure or to occurrence of adverse drug reactions such as agranulocytosis induced by its nonenzymatic metabolite amodiaquinequinoneimine.The aim of this study was to determine the frequency distribution of CYP2C8 mutant alleles particularly CYP2C8*2, CYP2C8*3 and CYP2C8*4 in one of the ethnic group that resides in malaria endemic area, Nias. PCR-RFLP analysis of 214 dot blot samples from Nias ethnic group subjects revealed that all of the samples carried the wild type allele of the CYP2C8 gene. In the absence of mutant alleles of CYP2C8 among Nias ethnic group, one can expect that treatment failure in amodiaquine therapy and adverse drug reactions associated with reactive metabolite of the drug are not related with CYP2C8 genetic polymorphisms."

"ABSTRAKLatar Belakang: Nefropati diabetik (ND) merupakan komplikasi mikrovaskular yang berkontribusi terhadap end stage renal disease (ESRD) pada penyandang DMT2. Polimorfisme gen apolipoprotein E (APOE) dihubungkan dengan dislipidemia merupakan faktor risiko untuk timbulnya ND.Tujuan: Mengetahui pengaruh polimorfisme gen APOE terhadap kejadian ND penyandang DMT2 di Palembang dan menganalisis pengaruh polimorfisme gen APOE terhadap perubahan profil lipid penyandang DMT2 dengan ND.Metode: Penelitian kasus kontrol pada penyandang DMT2 di Palembang. Kelompok kasus adalah penyandang DMT2 dengan ND dan kelompok kontrol adalah penyandang DMT2 tanpa ND yang memenuhi kriteria penyertaan.Hasil: Terdapat 37 penyandang DMT2 dengan ND (ACR > 300 mg/g kreatinin) dan 42 tanpa ND (ACR < 30 mg/g kreatinin). Tidak terdapat perbedaan bermakna pada usia, jenis kelamin, lama DM, tinggi badan, tekanan darah sistolik, glukosa darah puasa, HbA1c dan profil lipid. Terdapat perbedaan bermakna pada berat badan, IMT, TD diastolik, hemoglobin, ureum, kreatinin dan eGFR antara kasus dan kontrol. Distribusi genotip tidak berbeda bermakna. Pada kelompok kasus didapatkan peningkatan frekuensi alel gen APOE ε2 dibanding kontrol (62,2 % vs. 37,8 %). Dengan analisis bivariat didapatkan penyandang DMT2 yang mengandung alel gen APOE ε2 2,5 kali lipat dan bermakna (p = 0,023) dibandingkan gen APOE ε3 dalam menyebabkan ND sedangkan alel ε4 0,65 kali lipat dan tidak bermakna (p = 0,37). Profil lipid tidak berbeda bermakna baik pada penyandang DMT2 dengan ND maupun penyandang DMT2 tanpa nefropati.Simpulan: Frekuensi alel gen APOE ε2 lebih tinggi pada penyandang DMT2 dengan ND dibandingkan tanpa ND. Gen APOE ε2 merupakan faktor risiko kejadian ND pada penyandang DMT2. Tidak ada hubungan antara kejadian ND dengan perubahan profil lipid.

---

ABSTRACT

Backgrounds. Diabetic nephropathy is microvascular complication, largely contributed to end stage renal disease in T2DM patients. Apolipoprotein E (APOE) genetic polymorphism in association with dyslipidemia have been proposed as one of the risk factors for the development of diabetic nephropathy (DN).

Aim: To examine the effect of apolipoprotein E (APOE) gene polymorphism to DN incidence in patients with T2DM and to analyze the effect of APOE gene polymorphism to lipid profile in DN.

Method. Case control study at Palembang. Case group were T2DM with nephropathy and control group were T2DM without nephropathy.

Results. There were 37 patients with DN (ACR > 300 mg/g creatinine) and 42 patients without nephropathy (ACR < 30 mg/g creatinine). No significant differences in terms of age, sex, duration of DM, height, systolic blood pressure, fasting glucose, HbA1c and lipid profiles between the two groups. There were significant differences in weight, BMI, diastolic blood pressure, hemoglobine, ureum, creatinine and eGFR with p value 0.028, 0.013, 0.017, < 0.001, < 0.001, < 0.003 and < 0.002 respectively. The distribution of APOE genotypes between the two groups are the same. However, there was a significant difference in the allele frequencies, ε2 frequency was significantly higher in case group compared to control group (62.2 % vs. 37.8 %). On bivariate analysis ε2 allele showed 2.50 times to DN risk with p 0.023 while ε4 allele 0.65 times to DN risk. No significant difference in lipid profiles between DN and without nephropathy.

Conclusions. APOE ε2 allele was significantly higher in macroalbuminuria group. These result suggest that ε2 allele may be associated with the development of DN and ε2 allele was risk factor in T2DM patients. There were no correlation between APOE gene polymorphism and lipid profiles."

"Patogenesis nefropati diabetik (ND) merupakan hasil interaksi faktor hemodinamik, metabolik dan lingkungan serta faktor genetik. ND biasanya tidak terdeteksi secara klinis sampai terjadi kerusakan ginjal yang bermakna dapat berupa glomerulosklerosis, tubular atrofi dan fibrosis interstitial. KIM-1 dapat digunakan sebagai penanda adanya kerusakan tubulus ginjal. Hubungan polimorfisme gen ACE dengan nefropati diabetes masih tidak konsisten. Penelitian ini merupakan studi cross sectional komparasi antara dua kelompok penyandang DMT2 dengan atau tanpa nefropati yang bertujuan untuk mengetahui adanya kerusakan tubulus, polimorfisme gen ACE dan menganalisis hubungannya dengan kadar KIM-1 terhadap terjadinya kelainan tubulus. Didapatkan adanya peningkatan ekskresi KIM-1 urin pada 19 subjek pre-nefropati dengan median 1,3 (interquartile 1,5) ng/mL, 25 subjek nefropati insipien dengan median 1,6 (interquartile 2,3) ng/mL dan 12 subjek nefropati overt dengan rerata kadar KIM-1 3,1 ± 2,4 ng/mL. Terdapat polimorfisme gen ACE pada penyandang DMT2. Proporsi genotipe DD 9,3%, ID 33,3% dan II 57,4% pada kelompok NND, pada kelompok ND proporsi genotipe DD 4,7%, ID 34,1% dan genotipe II 61,2%. Dijumpai adanya hubungan bermakna antara alel D dengan peningkatan ekskresi KIM-1 urin pada kelompok pre-nefropati (p = 0,030). Peningkatan kadar KIM-1 urin pada kelompok pre-nefropati menunjukkan adanya kerusakan tubulus yang merupakan proses awal nefropati DM. Distribusi genotipe polimorfisme gen ACE pada penelitian ini menyerupai penelitian lain di negara-negara Asia, sedangkan di negara Eropa genotipe DD lebih banyak daripada genotipe II. Hubungan bermakna alel D dengan kadar KIM-1 hanya pada kelompok prenefropati mungkin disebabkan adanya faktor lain seperti kadar glukosa, kontrol glikemik, ureum, kreatinin dan kadar trigliserida yang memengaruhi. Simpulan: Terdapat peningkatan ekskresi KIM-1 urin pada penyandang DMT2 kelompok pre-nefropati yang meningkat secara bermakna pada penyandang DMT2 dengan nefropati overt. Peningkatan ekskresi KIM-1 urin dapat dipakai sebagai penanda kerusakan tubulus. Terdapat polimofisme gen ACE pada penyandang DMT2. Genotipe II lebih banyak dibanding genotipe ID dan DD. Dijumpai adanya hubungan alel D dengan peningkatan kadar KIM-1 urin pada penyandang DMT2 pre-nefropati.

---

The pathogenesis of nephropathy diabetic (ND) is the result of the interaction of haemodynamic, metabolic, environment, and genetic factors. In general, ND was clinically undetectable until kidney has been damaged significantly, in the form of glomerulosclerosis, tubular atrophy, or interstitial fibrosis. KIM-1 can be used as the initial indicator of kidney tubules damage. The relationship between ACE gene polymorphism and diabetic nephropathy was still inconsistent.

This research was a comparative cross-sectional study on two groups of DMT2 patients with and without nephropathy diabetic. The objectives of this study were to identify the tubules damage, ACE gene polymorphism, and to analyze the relationship between the degree of KIM-1 and the tubules damage. The increase of KIM-1 urine excretion was found in 19 pre-nephropathy subject (median = 1.3 with interquartile 1.5 ng/mL), in 25 incipient nephropathy subject (median = 1.6 (2.3) ng/mL), in 12 overt nephropathy subject (Mean = 3.1 ± 2,4 ng/mL). ACE polymorphism gene was found in DMT2 patients. In the NDD group, the genotype proportion of DD = 9.3%, ID = 33.3% and II = 57.4%. Whereas, in the ND group, the figures were 4.7%, 34.1% and 61.2%, respectively.

Significant relationship was found between allele D and the increase of KIM-1 urine on pre-nephropathy group (p = 0.030). The increase of KIM-1 urine on prenephropathy group shows the tubules damage which is the initial process of nephropathy diabetic. The genotype distribution of ACE gene polymorphism in this study was similar with the studies in Asian countries; however, in European countries the genotype DD is found higher than genotype II. The significant relationship between allele D and KIM-1 level in pre-nephropathy group might be the influence of other factors, such as glucose level, glycaemic control, urea, creatinine, and triglyceride level.

Conclusion: There was KIM-1 excretion increased on DMT2 pre-nephropathy group, which increase significantly in DMT2 overt nephropathy group. The increase of KIM-1 urine excretion can be used as the indicator of tubules damage. ACE gene polymorphism was found in DMT2 group, with genotype II was higher than genotype ID and DD. A significant relationship between allele D and the increase of KIM-1 urine excretion was found in pre-nephropathy group."

"Latar belakang: Polimorfisme genetik dari reseptor P2Y12 dikatakan dapatmempengaruhi aktivasi reseptor P2Y12 atau menghambat aktivasi trombosit. Beberapapolimorfisme nukleotida tunggal dalam gen P2Y12 ditemukan dapat menyebabkanvariabilitas antarindividu dalam agregasi platelet. Telah diidentifikasi limapolimorfisme dari gen P2Y12 yaitu T744C, C34T, G52T, ins801A, dan C139T. Salahsatunya, polimorfisme C34T adalah salah satu dari polimorfisme yang dikatakan adakaitannya dengan peningkatan agregasi platelet yang dapat menunjukkan kemungkinanuntuk terjadinya modifikasi respon terapi clopidogrel. Namun hingga saat ini belumada penelitian yang menilai hubungan langsung antara polimorfisme reseptor P2Y12dengan TIMI-flow beserta faktor-faktor yang mempengaruhinya, termasuk fungsipenghambatan platelet pada pasien IMA-EST yang menjalani IKPP.Tujuan: Penelitian ini bertujuan untuk mengetahui hubungan antara polimorfismenukleotida tunggal pada reseptor P2Y12 dengan TIMI flow beserta faktor-faktor yangmempengaruhinya, termasuk penghambatan fungsi platelet.Metode: Studi potong lintang pada 167 pasien IMA-EST yang menjalani IKPP.dilakukan pemeriksaan polimorfisme C34T reseptor P2Y12 dengan metode Taqmandan pemeriksaan fungsi penghambatan platelet yang diukur dengan VerifyNow P2Y12.Hasil: Dari 167 subjek penelitian, studi polimorfisme mengungkapkan proporsi pasiendengan heterozygous mutan sebanyak 34.1%, dan 1.8% pasien merupakan homozygousmutan. Sisanya adalah homozygous wildtype ditemukan sebanyak 64.1%. 25.7% pasientergolong non-responder terhadap clopidogrel. Secara keseluruhan tidak terdapathubungan secara langsung antara polimorfisme C34T dengan TIMI flow < 3, namunterdapat hubungan antara polimorfisme C34T dengan penurunan fungsi penghambatanplatelet (OR 2.17, p = 0.046).Kesimpulan: Tidak terdapat hubungan secara langsung antara polimorfisme C34Tdengan TIMI flow, namun pasien dengan polimorfisme C34T pada reseptor P2Y12memiliki risiko untuk mengalami penurunan penghambatan fungsi platelet.

---

Background: Genetic polymorphism of P2Y12 receptors is said to have affect of

P2Y12 receptor activation or inhibit platelet activation. Several single nucleotide

polymorphisms in the P2Y12 gene were found to cause variability between individuals

in platelet aggregation. Five polymorphisms have been identified from the P2Y12 gene,

namely T744C, C34T, G52T, ins801A, and C139T. One of them, C34T is one of the

polymorphisms that is said to be related to increased platelet aggregation which can

indicate the possibility for modification of the response of clopidogrel therapy. But until

now there has been no research that assesses the direct relationship between P2Y12

receptor polymorphisms and TIMI-flow along with the factors that influence it,

including the function of platelet inhibition in STEMI patients undergoing PPCI

Objective: This study aims to determine the relationship between single nucleotide

polymorphisms at P2Y12 receptors with TIMI flow along with the faktors that

influenced it, including inhibition of platelet function.

Methods: A cross-sectional study of 167 STEMI patients who underwent PPCI. C34T

polymorphism of P2Y12 receptor was evaluated by the Taqman method and the

inhibition of platelet function was measured by VerifyNow P2Y12.

Results: Among 167 subjects, the heterozygous mutants group were 34.1%, and 1.8%

of patients were homozygous mutants. The rest 64.1% was homozygous wildtype.

25.7% of patients were classified as non-responders to clopidogrel. Overall there was

no direct relationship between C34T polymorphisms and TIMI flow <3, but there was

a relationship between C34T polymorphisms and decreased platelet inhibitory function

(OR 2.17, p = 0.046).

Conclusion: There is no direct relationship between C34T polymorphisms and TIMI

flow, but patients with C34T polymorphisms of P2Y12 receptors have a risk of

decreasing platelet function inhibition."

"Sindrom koroner akut (SKA) merupakan kondisi ketidakseimbangan antara ketersediaan dan kebutuhan oksigen pada otot jantung yang disebabkan oleh obstruksi arteri koroner. Elevasi segmen-ST infark miokard (STEMI) akut terjadi ketika pasien dengan SKA mengalami oklusi total pada pembuluh arteri koroner. Penanganan utama untuk pasien dengan STEMI adalah terapi reperfusi menggunakan angioplasti primer. Thrombolysis in myocardial infarction (TIMI) flow grade merupakan metode penilaian aliran darah, dimana TIMI 0 flow menandakan tidak adanya perfusi dan TIMI 3 flow menandakan perfusi lengkap. Penelitian ini bertujuan untuk menentukan prediktor klinis pasien yang berhubungan dengan TIMI flow akhir 3. Penelitian ini merupakan studi cross-sectional analitik yang dilaksanakan melalui pengumpulan data karakteristik klinis pasien STEMI dan TIMI flow akhir dari Jakarta Acute Coronary Syndrome (JAC) Registry. Sampel penelitian melibatkan 3706 pasien STEMI yang diobati dengan angioplasti primer antara Februari 1, 2011 dan Agustus 31, 2019. Data dianalisis menggunakan IBM SPSS versi 20. TIMI flow akhir 3 berhubungan dengan durasi antara gejala awal dan terapi reperfusi ≤6 jam (p<0.001) dan dislipidemia (p = 0.008). Sedangkan, TIMI flow akhir <3 berhubungan dengan infark miokard pada dinding anterior jantung (p = 0.03) dan kadar kreatinin dalam darah di atas 1.2 mg/dl (p = 0.03). Durasi antara gejala awal dan terapi reperfusi yang lebih dini (≤6 jam) merupakan prediktor klinis terkuat untuk TIMI flow akhir 3.

---

Acute coronary syndrome (ACS) is an imbalance between oxygen supply and demand of the heart muscle due to an obstruction in the coronary artery. Acute ST-segment elevation myocardial infarction (STEMI) occurs when a patient with ACS has a complete coronary artery occlusion. The main treatment for patients with STEMI is reperfusion therapy using primary angioplasty. Thrombolysis in myocardial infarction (TIMI) flow grade is a method of measuring blood flow, where TIMI 0 flow indicates no perfusion and TIMI 3 flow indicates complete perfusion. This study is aimed to determine which clinical predictors are associated with final TIMI 3 flow. This is an analytical, cross-sectional study which was conducted through data collection of STEMI patients’ clinical characteristics and final TIMI flow from the Jakarta Acute Coronary Syndrome (JAC) Registry. The study samples include 3706 STEMI patients who were treated with primary angioplasty between February 1, 2011 and August 31, 2019. The data was analyzed using IBM SPSS version 20. Final TIMI 3 flow is associated with the duration between symptom onset and reperfusion therapy of ≤6 hours (p<0.001) and dyslipidemia (p = 0.008). Meanwhile, final TIMI <3 flow is associated with anterior wall myocardial infarction (p = 0.03) and creatinine level above 1.2 mg/dl (p = 0.03). An earlier duration between symptom onset and reperfusion therapy (≤6 hours) is the strongest clinical predictor of final TIMI 3 flow."

"Studi mengenai pemberian klopidogrel sebelum angiografi koroner (pretreatment) pada pasien infark miokard akut dengan elevasi segmen ST (IMA-EST) yang akan menjalani intervensi koroner perkutan primer (IKPP) terbatas, namun dapat disimpulkan bahwa aman dan dapat penurunan angka major adverse cardiovascular events (MACE). Pada studi yang dilakukan beberapa tahun terakhir, manfaat pemberian klopidogrel pretreatment dipertanyakan. Studi yang telah ada dilakukan di negara lain berbeda dengan kondisi di Indonesia; terdapat perbedaan karakteristik seperti waktu onset nyeri dada hingga pasien sampai ke fasilitas kesehatan primer, loading antiplatelet, serta dilakukan tindakan IKPP yang lebih panjang. Penelitian ini bertujuan untuk mengetahui hubungan pemberian klopidogrel pretreatment  dengan TIMI-flow pasien IMA EST yang menjalani IKPP. Studi potong lintang retrospektif terhadap 220 pasien IMA EST dilakukan di rumah sakit Jantung dan Pembuluh Darah Harapan Kita sejak tanggal 1 Januari - 30 Oktober 2018 dengan membagi subjek dalam kelompok klopidogrel pretreatment (600 mg klopidogrel diberikan > 120 menit sebelum angiografi koroner) dan kelompok yang diberikan < 120 menit. Analisis multivariat menunjukkan bahwa klopidogrel pretreatment merupakan prediktor utama yang mempengaruhi TIMI flow sebelum tindakan IKPP (OR 0.273, 95% CI 0.104-0.716; p=0.008). Pemberian klopidogrel pretreatment berhubungan dengan TIMI flow sebelum tindakan IKPP, namun tidak berpengaruh terhadap TIMI setelah dilakukan tindakan IKPP. 

---

Immediate antiplatelet administration is the standard therapy used in acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. Studi on clopidogrel pretreatment are limited, but it can be concluded that was safe, also reduced the number of major adverse cardiovascular events (MACE). Recently, pretreatment with P2Y12 are questioned. There are differences in the background and the conditions between the studies that have been conducted and the condition in Indonesia; such as duration of angina onset until arrive at primary health care, time of loading antiplatelet and longer ischemic time.

This study sought to evaluate the association between clopidogrel pretreatment and TIMI flow of patients with acute STEMI undergoing primary PCI. Single-center retrospective cross sectional study of 220 patients with acute STEMI were conducted in National Centre of Cardiovascular Harapan Kita, Indonesia from 1 January-30 October 2018. Subjects are devided into two groups: clopidogrel pretreatment (≥ 120 minute from coronary angiography conducted) and non pretreatment group (<120 minute). Multivariate analysis revealed that clopidogrel pretreatment is the main predictor of preprocedural TIMI grade flow (OR 0.273, 95% CI 0.104-0.716; p=0.008). Clopidogrel pretreatement was associated with TIMI flow grade pre intervention, but not with TIMI flow grade post intervention."

"Pendahuluan: Gen Interleukin 6 IL-6 merupakan gen yang mengkode protein sitokin yang menjaga homeostasis imun dan memainkan peran penting dalam inflamasi dan patogenesis berbagai penyakit. Dalam beberapa penelitian sebelumnya, polimorfisme pada promoter gen IL-6 dibuktikan memiliki hubungan bermakna dengan risiko terjadinya karsinoma sel skuamosa regio kepala dan leher. Tujuan: Mendeteksi polimorfisme gen IL-6 -174G/C pada penderita karsinoma sel skuamosa populasi Indonesia. Metode: Metode PCR-RFLP dilakukan pada 85 sampel penderita KSSKL dengan enzim restriksi Nla III yang divisualisasi dengan elektroforesis. Hasil: Polimorfisme gen IL-6 -174G/C ditemukan pada sampel yang diteliti sebesar 2.3. Kesimpulan: Polimorfisme genetik interleukin 6 meningkatkan risiko KSSKL di populasi Indonesia.

---

Introduction: Interleukin 6 IL 6 gene encodes a cytokine protein which maintains immune homeostasis and plays essential roles in inflammation and diseases rsquo pathogenesis. In previous studies, polymorphism of interleukin 6 gene promoter was found significantly associated with the head and neck squamous cell carcinoma risk.

Objectives: To detect the polymorphism of IL 6 174G C in Indonesian head and neck squamous cell carcinoma HNSCC patients.

Methods: PCR RFLP method was used to analyze 85 samples of HNSCC patients, using Nla III restriction enzyme and the results were visualized by electrophoresis.

Results: IL 6 174G C gene polymorphisms were found in the studied samples 2.3 .

Conclusion: IL 6 174G C gene polymorphisms increased the risk of HNSCC in Indonesian population."

"Latar belakang: Polimorfisme Gly972Arg pada gen IRS1 dapat mengganggufungsi normal endotel dan menyebabkan disfungsi endotel. TIMI flow pascaprosedur IKPP dan jumlah pembuluh darah yang terlibat pada pasien IMA-ESTmerupakan prediktor mortalitas dan morbiditas selama perawatan. Mekanismeyang menyebabkan adanya perbedaan profil angiografi ini salah satunyadipengaruhi oleh difungsi endotel di tingkat mikrovaskular dan makrovaskular.Penelitian mengenai hubungan antara polimorfisme Gly972Arg pada gen IRS1dengan TIMI flow pasca prosedur dan jumlah keterlibatan pembuluh darah belumpernah dilakukan.Tujuan: Penelitian ini bertujuan untuk mengetahui hubungan antara polimorfismeGly972Arg pada IRS1 dengan TIMI flow pasca IKPP dan jumlah keterlibatanpembuluh darah pada pasien IMA-EST.Metode: Studi potong lintang pada 104 pasien IMA-EST RSJPDHK yangmenjalani IKPP yang masuk pada registri 2018. Pemeriksaan polimorfismeGly972Arg pada IRS1 dengan menggunakan metode Taqman.Hasil: Terdapat 104 subjek yang diikutsertakan dalam penelitian ini. Subjek dibagidalam 3 kelompok, yakni grup wildtype/CC (42,3%), heterozigot/CT (49,0%), danhomozigot mutan/TT (8,7%). Tidak terdapat hubungan yang bermakna antarakelompok mutan (TT) dengan TIMI flow pasca IKPP (OR 0,8; p = 1,000) danjumlah keterlibatan pembuluh darah (OR 0,3; p = 0,163).Kesimpulan: Tidak terdapat hubungan antara polimorfisme Gly972Arg gen IRS1dengan TIMI flow pasca IKPP dan jumlah keterlibatan pembuluh darah pasien IMAEST.

---

Background: Gly972Arg polymorphism of IRS1 gene can interfere with normalendothelial function and cause endothelial dysfunction. TIMI flow after the primarypercutaneous intervention procedure and the number of coronary vessels involvedin STEMI patients are predictors that determine mortality and morbidity duringtreatment. The mechanism that causes this difference in angiographic profile isinfluenced by endothelial dysfunction at the microvascular and macrovascularlevels. Research on the relationship between Gly972Arg polymorphisms of IRS1gene with TIMI flow post procedure and the amount of blood vessel involvementhas not been carried out.Objective: We sought to define whether Gly972Arg polymorphisms of IRS1 genemay affect TIMI flow after primary percutaneous intervention and number ofcoronary vessel involved.Methods: Cross-sectional study design of 104 STEMI patients who underwentprimary PCI at National Cardiovascular Center Harapan Kita Hospital at year 2018.Examination of Gly972Arg polymorphism on IRS1 is using the Taqman methodPCR.Results: There were 104 of STEMI patients who underwent primary PCI andrecruited for the study. The subjects then divided into 3 categories, which arewildtype/CC (42,3%), carrier/CT (49,0%) and mutant/TT (8,7%). There were nosignificant relationship between the mutant group (TT) with TIMI flow afterprimary PCI (OR 0.8; p = 1,000) and the number of coronary vessel involvement(OR 0.3; p = 0.163).Conclusion: There were no relationship between the Gly972Arg polymorphism ofIRS1 gene with TIMI flow after primary PCI and the number of coronary vesselinvolvement of STEMI patients."